Literature DB >> 24760723

Risk factors for bleeding in hepatocellular adenoma.

M Bieze1, S S K S Phoa, J Verheij, K P van Lienden, T M van Gulik.   

Abstract

BACKGROUND: Hepatocellular adenoma (HCA) is a benign hepatic lesion that may be complicated by bleeding, although the risk of bleeding is ill-defined. The aim of this study was to assess risk factors for bleeding in patients diagnosed with HCA.
METHODS: Patients with HCA were included prospectively from January 2008 to July 2012. Patient characteristics were noted. Patients underwent dynamic magnetic resonance imaging (MRI) and/or computed tomography (CT) at presentation and during follow-up. Lesion characteristics on (follow-up) imaging were noted, and bleeding was graded as intratumoral (grade I), intrahepatic (grade II) or extrahepatic (grade III). The standard of reference for diagnosis was histopathology, or dynamic MRI and/or CT findings. Possible risk factors were included if mentioned in literature (lesion size, body mass index), or based on clinical experience (lesion location, visible vessels on imaging).
RESULTS: A total of 45 patients (median age 39 (range 22-60) years; 44 women) with 195 lesions (median size 24 (10-250) mm) were evaluated. Bleeding occurred in 29 patients (64 per cent) and in 42 lesions (21.5 per cent) with a median size of 62 (10-160) mm. Size was a risk factor for bleeding (P < 0.001), with an increased number of bleeding events in lesions of 35 mm or more. Exophytic lesions (protruding from liver) had more bleeding (16 of 24, 67 per cent) than intrahepatic (9 of 82, 11 per cent) or subcapsular (17 of 89, 19 per cent) lesions (P < 0.001). Lesions in segments II and III had more bleeds than those in the right liver (11 of 32 versus 31 of 163; P = 0.049), as did lesions in which peripheral or central arteries were visualized on imaging (10 of 13 versus 32 of 182 lesions with no visible vascularization; P < 0.001).
CONCLUSION: Risk factors for bleeding of HCA include diameter of 35 mm or more, visualization of lesional arteries, location in the left lateral liver, and exophytic growth.
© 2014 BJS Society Ltd. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24760723     DOI: 10.1002/bjs.9493

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  24 in total

Review 1.  Benign solid tumors of the liver: management in the modern era.

Authors:  Georgios Antonios Margonis; Aslam Ejaz; Gaya Spolverato; Neda Rastegar; Robert Anders; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-01-06       Impact factor: 3.452

2.  Short-term outcomes of laparoscopic vs. open liver resection for hepatocellular adenoma: a multicenter propensity score adjustment analysis by the AFC-HCA-2013 study group.

Authors:  Filippo Landi; Nicola De' Angelis; Olivier Scatton; Xavier Vidal; Ahmet Ayav; Fabrice Muscari; Safi Dokmak; Guido Torzilli; Nicolas Demartines; Olivier Soubrane; Daniel Cherqui; Jean Hardwigsen; Alexis Laurent
Journal:  Surg Endosc       Date:  2017-03-09       Impact factor: 4.584

3.  European experience of 573 liver resections for hepatocellular adenoma: a cross-sectional study by the AFC-HCA-2013 study group.

Authors:  Alexis Laurent; Safi Dokmak; Jean-Charles Nault; François-René Pruvot; Jean-Michel Fabre; Christian Letoublon; Philippe Bachellier; Lorenzo Capussotti; Olivier Farges; Jean-Yves Mabrut; Yves-Patrice Le Treut; Ahmet Ayav; Bertrand Suc; Olivier Soubrane; Gilles Mentha; Irinel Popescu; Marco Montorsi; Nicolas Demartines; Jacques Belghiti; Guido Torzilli; Daniel Cherqui; Jean Hardwigsen
Journal:  HPB (Oxford)       Date:  2016-07-22       Impact factor: 3.647

4.  Long-term outcomes of resection in patients with symptomatic benign liver tumours.

Authors:  Belle V van Rosmalen; Matthanja Bieze; Marc G H Besselink; Pieter Tanis; Joanne Verheij; Saffire S K S Phoa; Olivier Busch; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2016-08-21       Impact factor: 3.647

5.  [Focal nodular hyperplasia and hepatocellular adenoma].

Authors:  N Bastati-Huber; S Pötter-Lang; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-01       Impact factor: 0.635

Review 6.  Benign liver tumours: understanding molecular physiology to adapt clinical management.

Authors:  Jean-Charles Nault; Valérie Paradis; Maxime Ronot; Jessica Zucman-Rossi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-07-14       Impact factor: 73.082

Review 7.  Current Approaches in the Management of Hepatic Adenomas.

Authors:  Diamantis I Tsilimigras; Amir A Rahnemai-Azar; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Demetrios Moris; Eleftherios Spartalis; Jordan M Cloyd; Sharon M Weber; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-08-14       Impact factor: 3.452

Review 8.  Hepatocellular adenoma: An update.

Authors:  Adarsh Vijay; Ahmed Elaffandi; Hatem Khalaf
Journal:  World J Hepatol       Date:  2015-11-08

9.  Current updates on the molecular genetics and magnetic resonance imaging of focal nodular hyperplasia and hepatocellular adenoma.

Authors:  Maneesh Khanna; Subramaniyan Ramanathan; Najla Fasih; Nicola Schieda; Vivek Virmani; Matthew D F McInnes
Journal:  Insights Imaging       Date:  2015-03-20

Review 10.  Hepatocellular adenoma: when and how to treat? Update of current evidence.

Authors:  Maarten G Thomeer; Mirelle Broker; Joanne Verheij; Michael Doukas; Turkan Terkivatan; Diederick Bijdevaate; Robert A De Man; Adriaan Moelker; Jan N IJzermans
Journal:  Therap Adv Gastroenterol       Date:  2016-09-28       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.